Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generic User Fee Transition A Little Bumpy For Contract Manufacturers

Nov 01 2017

• By Derrick Gingery

US-Money-and-Pills_V2_1200x675

Related Content

US FDA Changes Data Source For GDUFA II Facility Fee Setting

Aug 29 2017

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

Aug 28 2017

Generic Drug Sponsors Seek Advance Notice Of Approvals From US FDA

May 17 2017

ANDA Communication Complaints: FDA Takes Licking, Keeps Ticking

Sep 22 2014

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Sep 26 2016

Additional Topics

United States Generic Drugs Manufacturing FDA Regulation BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window